Anti-angiogenic therapies in cancer clinical trials. (Q36181120)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15991906 AND SRC:MED&resulttype=core&format=json

13 January 2020

title

Anti-angiogenic therapies in cancer clinical trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15991906 AND SRC:MED&resulttype=core&format=json

13 January 2020

main subject

angiogenesis inhibitor

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15991906 AND SRC:MED&resulttype=core&format=json

13 January 2020

author name string

H T Zhang

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15991906 AND SRC:MED&resulttype=core&format=json

13 January 2020

language of work or name

English

0 references

publication date

1 October 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15991906 AND SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

13 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15991906 AND SRC:MED&resulttype=core&format=json

13 January 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15991906 AND SRC:MED&resulttype=core&format=json

13 January 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15991906 AND SRC:MED&resulttype=core&format=json

13 January 2020

page(s)

1629-1655

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15991906 AND SRC:MED&resulttype=core&format=json

Angiogenesis antagonists: current clinical trials

13 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

New anti-angiogenesis agents: review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

The clinical experience with antiangiogenic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Clinical research on antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Metastases and the normalization of tumour blood vessels by ICRF 159: a new type of drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): progress in supportive care

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Chelation Therapy in Cardiovascular Disease: Ethylenediaminetetraacetic Acid, Deferoxamine, and Dexrazoxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Therapeutic uses of heparin beyond its traditional role as an anticoagulant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

The anti-proliferative effect of suramin towards tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and insulin-like growth factor-I: growth stimulation in the presence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Suramin Is an Active Site-directed, Reversible, and Tight-binding Inhibitor of Protein-tyrosine Phosphatases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

A structure-activity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Leflunomide and malononitrilamides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Matrix Metalloproteinase Inhibition as a Novel Anticancer Strategy: A Review with Special Focus on Batimastat and Marimastat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Preclinical antitumor activity of CI-994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Preclinical toxicity of a new oral anticancer drug, CI-994 (Acetyldinaline), in rats and dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Soluble E-selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor-inhibiting anti-neovascularization agent, evaluated in phase I clinical trail

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Cytokine Gene Therapy of Cancer Using Gene Gun Technology: Superior Antitumor Activity of Interleukin-12

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Phase I trial of pentosan polysulfate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

A phase I study of pentosan polysulfate sodium in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Administration of Pentosan Polysulfate to Patients With Human Immunodeficiency Virus-Associated Kaposi's Sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Angiosuppressive therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Stretch-induced VEGF expression in the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Bryostatin 1-tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Biological activity of 26-succinylbryostatin 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Effects of Thalidomide and Related Metabolites in a Mouse Corneal Model of Neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Immunologic and biochemical analysis of TNT-1 and TNT-2 monoclonal antibody binding to histones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Effect of a xanthine analog on human hepatocellular carcinoma cells (Alexander) in culture and in xenografts in SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Squalamine: an aminosterol antibiotic from the shark

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

The aminosterol antibiotic squalamine permeabilizes large unilamellar phospholipid vesicles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Inhibition of angiogenesis by anthracyclines and titanocene dichloride

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Disruption of Angiogenesis by PEX, a Noncatalytic Metalloproteinase Fragment with Integrin Binding Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Angiostatin and endostatin: endothelial cell-specific endogenous inhibitors of angiogenesis and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.7.10.1629

10.1517/13543784.7.10.1629

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15991906 AND SRC:MED&resulttype=core&format=json

release_imemkbwd4ncpdkztba3xcwosxe

13 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/imemkbwd4ncpdkztba3xcwosxe

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference